Myriad Genetics, Inc. (0K3W.L)
USD 8.13
(0.12%)
USD 8.13
(0.12%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2022 | 20.1 Million USD | 31.37% |
| 2021 | 15.3 Million USD | -43.54% |
| 2020 | 27.1 Million USD | -13.69% |
| 2019 | 31.4 Million USD | 0.0% |
| 2018 | 31.4 Million USD | -8.45% |
| 2017 | 34.3 Million USD | -18.72% |
| 2016 | 42.2 Million USD | 10.18% |
| 2015 | 38.3 Million USD | 52.59% |
| 2014 | 25.1 Million USD | 4.94% |
| 2013 | 23.91 Million USD | 377.71% |
| 2012 | 5 Million USD | -56.74% |
| 2011 | 11.57 Million USD | 104.2% |
| 2010 | 5.66 Million USD | 101.42% |
| 2009 | -399.17 Million USD | 0.0% |
| 2008 | - USD | 0.0% |
| 2007 | - USD | 0.0% |
| 2006 | - USD | 0.0% |
| 2005 | - USD | 0.0% |
| 2004 | - USD | 0.0% |
| 2003 | - USD | 0.0% |
| 2002 | - USD | 0.0% |
| 2001 | - USD | 0.0% |
| 2000 | - USD | 0.0% |
| 1999 | - USD | 0.0% |
| 1998 | - USD | 0.0% |
| 1997 | - USD | 0.0% |
| 1996 | - USD | 0.0% |
| 1995 | - USD | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 Q1 | 21.8 Million USD | 8.46% |
| 2023 Q3 | 25.1 Million USD | 11.56% |
| 2023 Q2 | 22.5 Million USD | 3.21% |
| 2022 Q4 | 20.1 Million USD | 2.55% |
| 2022 Q1 | 15.6 Million USD | 1.96% |
| 2022 Q3 | 19.6 Million USD | 27.27% |
| 2022 Q2 | 15.4 Million USD | -1.28% |
| 2022 FY | 20.1 Million USD | 31.37% |
| 2021 FY | 15.3 Million USD | -43.54% |
| 2021 Q2 | 17.7 Million USD | -28.05% |
| 2021 Q3 | 18.6 Million USD | 5.08% |
| 2021 Q4 | 15.3 Million USD | -17.74% |
| 2021 Q1 | 24.6 Million USD | -9.23% |
| 2020 Q1 | 30.8 Million USD | 9.61% |
| 2020 Q3 | 26.6 Million USD | -8.59% |
| 2020 Q2 | 29.1 Million USD | -5.52% |
| 2020 FY | 27.1 Million USD | -13.69% |
| 2020 Q4 | 27.1 Million USD | 1.88% |
| 2019 Q4 | 28.1 Million USD | 0.0% |
| 2019 Q2 | 31.4 Million USD | -1.57% |
| 2019 FY | 31.4 Million USD | 0.0% |
| 2019 Q1 | 31.9 Million USD | -4.2% |
| 2019 Q3 | 28.1 Million USD | -10.51% |
| 2018 FY | 31.4 Million USD | -8.45% |
| 2018 Q1 | 33.4 Million USD | -12.57% |
| 2018 Q2 | 34.3 Million USD | 2.69% |
| 2018 Q3 | 35.9 Million USD | 4.66% |
| 2018 Q4 | 33.3 Million USD | -7.24% |
| 2017 Q4 | 38.2 Million USD | -1.8% |
| 2017 FY | 34.3 Million USD | -18.72% |
| 2017 Q3 | 38.9 Million USD | -7.82% |
| 2017 Q2 | 42.2 Million USD | -10.97% |
| 2017 Q1 | 47.4 Million USD | -7.6% |
| 2016 Q2 | 38.3 Million USD | 51.38% |
| 2016 FY | 42.2 Million USD | 10.18% |
| 2016 Q4 | 51.3 Million USD | -4.82% |
| 2016 Q1 | 25.3 Million USD | -13.06% |
| 2016 Q3 | 53.9 Million USD | 40.73% |
| 2015 FY | 38.3 Million USD | 52.59% |
| 2015 Q3 | 34.3 Million USD | 36.65% |
| 2015 Q4 | 29.1 Million USD | -15.16% |
| 2015 Q2 | 25.1 Million USD | -14.51% |
| 2015 Q1 | 29.35 Million USD | 45.54% |
| 2014 Q1 | 18.9 Million USD | 308.35% |
| 2014 Q4 | 20.17 Million USD | -18.58% |
| 2014 Q2 | 23.91 Million USD | 26.52% |
| 2014 FY | 25.1 Million USD | 4.94% |
| 2014 Q3 | 24.77 Million USD | 3.58% |
| 2013 Q1 | 7.13 Million USD | -31.82% |
| 2013 Q4 | -9.07 Million USD | -3.49% |
| 2013 Q3 | -8.76 Million USD | -275.11% |
| 2013 Q2 | 5 Million USD | -29.83% |
| 2013 FY | 23.91 Million USD | 377.71% |
| 2012 FY | 5 Million USD | -56.74% |
| 2012 Q4 | 10.46 Million USD | -1.27% |
| 2012 Q1 | 10.38 Million USD | 0.86% |
| 2012 Q2 | 11.57 Million USD | 11.47% |
| 2012 Q3 | 10.6 Million USD | -8.4% |
| 2011 Q2 | 5.66 Million USD | 101.58% |
| 2011 FY | 11.57 Million USD | 104.2% |
| 2011 Q4 | 10.29 Million USD | 6.09% |
| 2011 Q3 | 9.7 Million USD | 71.19% |
| 2011 Q1 | -358.98 Million USD | 7.41% |
| 2010 Q3 | - USD | -100.0% |
| 2010 Q4 | -387.7 Million USD | 0.0% |
| 2010 FY | 5.66 Million USD | 101.42% |
| 2010 Q1 | -395.74 Million USD | 0.0% |
| 2010 Q2 | 22.61 Million USD | 105.71% |
| 2009 Q1 | - USD | 0.0% |
| 2009 Q4 | - USD | 0.0% |
| 2009 Q2 | - USD | 0.0% |
| 2009 FY | -399.17 Million USD | 0.0% |
| 2009 Q3 | - USD | 0.0% |
| 2008 Q2 | - USD | 0.0% |
| 2008 Q4 | - USD | 0.0% |
| 2008 FY | - USD | 0.0% |
| 2008 Q1 | - USD | 0.0% |
| 2008 Q3 | - USD | 0.0% |
| 2007 Q4 | - USD | 0.0% |
| 2007 Q1 | - USD | 0.0% |
| 2007 FY | - USD | 0.0% |
| 2007 Q2 | - USD | 0.0% |
| 2007 Q3 | - USD | 0.0% |
| 2006 Q4 | - USD | 0.0% |
| 2006 FY | - USD | 0.0% |
| 2006 Q3 | - USD | 0.0% |
| 2006 Q1 | - USD | 0.0% |
| 2006 Q2 | - USD | 0.0% |
| 2005 Q3 | - USD | 0.0% |
| 2005 FY | - USD | 0.0% |
| 2005 Q1 | - USD | 0.0% |
| 2005 Q2 | - USD | 0.0% |
| 2005 Q4 | - USD | 0.0% |
| 2004 Q4 | - USD | 0.0% |
| 2004 Q2 | - USD | 0.0% |
| 2004 FY | - USD | 0.0% |
| 2004 Q3 | - USD | 0.0% |
| 2004 Q1 | - USD | 0.0% |
| 2003 Q1 | - USD | 0.0% |
| 2003 Q4 | - USD | 0.0% |
| 2003 Q3 | - USD | 0.0% |
| 2003 Q2 | - USD | 0.0% |
| 2003 FY | - USD | 0.0% |
| 2002 FY | - USD | 0.0% |
| 2002 Q2 | - USD | 0.0% |
| 2002 Q3 | - USD | 0.0% |
| 2002 Q1 | - USD | 0.0% |
| 2002 Q4 | - USD | 0.0% |
| 2001 Q3 | - USD | 0.0% |
| 2001 Q1 | - USD | 0.0% |
| 2001 Q2 | - USD | 0.0% |
| 2001 Q4 | - USD | 0.0% |
| 2001 FY | - USD | 0.0% |
| 2000 Q3 | - USD | 0.0% |
| 2000 Q4 | - USD | 0.0% |
| 2000 Q2 | - USD | 0.0% |
| 2000 Q1 | - USD | 0.0% |
| 2000 FY | - USD | 0.0% |
| 1999 Q2 | - USD | 0.0% |
| 1999 Q4 | - USD | 0.0% |
| 1999 Q3 | - USD | 0.0% |
| 1999 FY | - USD | 0.0% |
| 1999 Q1 | - USD | 0.0% |
| 1998 Q3 | - USD | 0.0% |
| 1998 FY | - USD | 0.0% |
| 1998 Q4 | - USD | 0.0% |
| 1998 Q1 | - USD | 0.0% |
| 1998 Q2 | - USD | 0.0% |
| 1997 Q3 | - USD | 0.0% |
| 1997 FY | - USD | 0.0% |
| 1997 Q4 | - USD | 0.0% |
| 1997 Q1 | - USD | 0.0% |
| 1997 Q2 | - USD | 0.0% |
| 1996 Q2 | - USD | 0.0% |
| 1996 Q1 | - USD | 0.0% |
| 1996 FY | - USD | 0.0% |
| 1996 Q4 | - USD | 0.0% |
| 1996 Q3 | - USD | 0.0% |
| 1995 Q4 | - USD | 0.0% |
| 1995 FY | - USD | 0.0% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| uniQure N.V. | 12.02 Million USD | -67.166% |
| Agios Pharmaceuticals, Inc. | 19.07 Million USD | -5.368% |
| Amicus Therapeutics, Inc. | 59.69 Million USD | 66.329% |
| Atara Biotherapeutics, Inc. | 9.7 Million USD | -107.088% |
| bluebird bio, Inc. | 22.91 Million USD | 12.3% |
| Cara Therapeutics, Inc. | 2.82 Million USD | -612.513% |
| Imunon, Inc. | - USD | -Infinity% |
| Editas Medicine, Inc. | - USD | -Infinity% |
| IQVIA Holdings Inc. | - USD | -Infinity% |
| Mettler-Toledo International Inc. | 385.86 Million USD | 94.791% |
| Neurocrine Biosciences, Inc. | 38.3 Million USD | 47.52% |
| Supernus Pharmaceuticals, Inc. | 77.4 Million USD | 74.034% |
| Verastem, Inc. | - USD | -Infinity% |
| Walgreens Boots Alliance, Inc. | 8.32 Billion USD | 99.758% |
| Waters Corporation | 516.23 Million USD | 96.106% |
| Thermo Fisher Scientific Inc. | 5.08 Billion USD | 99.605% |
| Biogen Inc. | 2.52 Billion USD | 99.205% |
| Nektar Therapeutics | 16.1 Million USD | -24.837% |
| Perrigo Company plc | 1.14 Billion USD | 98.238% |
| Dynavax Technologies Corporation | 53.29 Million USD | 62.282% |
| Illumina, Inc. | 587 Million USD | 96.576% |
| Corbus Pharmaceuticals Holdings, Inc. | - USD | -Infinity% |
| Iovance Biotherapeutics, Inc. | 10.37 Million USD | -93.791% |
| Heron Therapeutics, Inc. | 42.11 Million USD | 52.268% |
| Unity Biotechnology, Inc. | - USD | -Infinity% |
| BioMarin Pharmaceutical Inc. | 1.1 Billion USD | 98.185% |
| Sangamo Therapeutics, Inc. | - USD | -Infinity% |
| Evolus, Inc. | 10.99 Million USD | -82.761% |
| Adicet Bio, Inc. | - USD | -Infinity% |
| Aclaris Therapeutics, Inc. | - USD | -Infinity% |
| Regeneron Pharmaceuticals, Inc. | 2.58 Billion USD | 99.221% |
| Esperion Therapeutics, Inc. | 65.62 Million USD | 69.37% |
| FibroGen, Inc. | 41.56 Million USD | 51.642% |
| Agilent Technologies, Inc. | 1.03 Billion USD | 98.05% |
| OPKO Health, Inc. | 65.69 Million USD | 69.405% |
| Homology Medicines, Inc. | - USD | -Infinity% |
| Geron Corporation | - USD | -Infinity% |
| Alnylam Pharmaceuticals, Inc. | 89.14 Million USD | 77.453% |
| Exelixis, Inc. | 17.32 Million USD | -16.031% |
| Viking Therapeutics, Inc. | - USD | -Infinity% |
| Anavex Life Sciences Corp. | - USD | -Infinity% |
| Intellia Therapeutics, Inc. | - USD | -Infinity% |
| Zoetis Inc. | 2.56 Billion USD | 99.216% |
| Axsome Therapeutics, Inc. | 15.13 Million USD | -32.805% |
| Abeona Therapeutics Inc. | -2.44 Million USD | 922.422% |
| Vertex Pharmaceuticals Incorporated | 738.8 Million USD | 97.279% |
| Kala Pharmaceuticals, Inc. | - USD | -Infinity% |
| Ionis Pharmaceuticals, Inc. | 28.42 Million USD | 29.288% |
| Sarepta Therapeutics, Inc. | 322.85 Million USD | 93.774% |
| Corcept Therapeutics Incorporated | 7.73 Million USD | -160.026% |
| Halozyme Therapeutics, Inc. | 127.6 Million USD | 84.248% |
| Blueprint Medicines Corporation | 21.22 Million USD | 5.291% |
| Insmed Incorporated | 83.24 Million USD | 75.855% |
| TG Therapeutics, Inc. | 39.82 Million USD | 49.527% |
| Incyte Corporation | 62.97 Million USD | 68.081% |
| Emergent BioSolutions Inc. | 328.9 Million USD | 93.889% |